2021 Fiscal Year Final Research Report
Effects of C-reactive protein and nuclear receptors on pharmacokinetics of voriconazole
Project/Area Number |
18K06778
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 47060:Clinical pharmacy-related
|
Research Institution | Hirosaki University |
Principal Investigator |
|
Project Period (FY) |
2018-04-01 – 2022-03-31
|
Keywords | ボリコナゾール / ボリコナゾールN-オキシド体 / 炎症反応 / CYP2C19遺伝子多型 / 核内受容体遺伝子多型 |
Outline of Final Research Achievements |
The effects of polymorphisms of pharmacokinetics‐related genes and the inflammatory response on the ratio of voriconazole (VRCZ) N-oxide to VRCZ (VNO/VRCZ) and steady-state dose-adjusted trough concentrations (C0h/D) of VRCZ were investigated. Results of multiple linear regression analyses demonstrated that the presence of the CYP2C19*1/*1 genotype and the presence of the NR1I2 rs3814057 C/C genotype were independent factors influencing the VNO/VRCZ ratio and C0/D in patients with CRP levels of less than 4 mg/dL. On the contrary, in patients with CRP levels of at least 4 mg/dL, no independent factors were found to affect these.
|
Free Research Field |
臨床薬理学
|
Academic Significance and Societal Importance of the Research Achievements |
抗真菌薬であるボリコナゾールは、血中濃度治療域が狭く、かつ、個体内-個体間変動も大きいため、最適な投与量を決定するのに難渋する。したがって、ボリコナゾールの血中動態に影響を及ぼす要因を特定できれば、投与量の個別化において有用な情報となり得る。本研究を通じ、我々は、CYP2C19遺伝子多型、プレグナンX受容体遺伝子多型、及び炎症反応(CRP)が、ボリコナゾールの血中動態に影響を及ぼすことを明らかにした。これらの結果は、ボリコナゾールの適正使用推進に繋がるものと考えられる。
|